Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 16/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 16/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 16/20 | 1.00 |
| ▸ | FLT1 | P17948 | 12/20 | 1.00 |
| ▸ | FLT4 | P35916 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 12/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CSK | P41240 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.70 |
| ▸ | PRKCG | P05129 | 1/20 | 0.70 |
| ▸ | PRKCB | P05771 | 1/20 | 0.70 |
| ▸ | PRKCA | P17252 | 1/20 | 0.70 |
| ▸ | PRKCH | P24723 | 1/20 | 0.70 |
| ▸ | PRKCI | P41743 | 1/20 | 0.70 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-173074 SCHEMBL29828472 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL22144559 | 0.98 | FGFR1 (0.95) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL16489372 | 0.95 | FGFR1 (0.91) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL17814860 | 0.95 | FGFR1 (0.90) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL15624527 | 0.93 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL3479994 | 0.93 | FGFR1 (0.87) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL21780972 | 0.92 | FGFR1 (0.85) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL23224727 | 0.91 | FGFR1 (0.83) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL19338047 | 0.90 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3FLT1 | |
| SCHEMBL30738006 | 0.90 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-20260002124-A1 | ENHANCING NEURONAL DIFFERENTIATION OF VENTRAL MIDBRAIN NEURAL PROGENITOR CELLS | NOVO NORDISK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025216949-A1 | METHODS FOR TREATING A TUMOR WITH ANTI-CDH6 ANTIBODY DRUG CONJUGATES | ONCUSP THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-3047017-B1 | METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250250646-A1 | DUAL GENETIC REPORTERS IN HUMAN PLURIPOTENT CELLS FOR USE AS ALTERNATIVE TO MOUSE EMBRYO ASSAY | NEXPRING US OPCO INC. | 2025-08-07 | — | — | US | claimed |
| US-20250230208-A1 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | ABIONYX PHARMA SA (FR) | 2025-07-17 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-3183336-B2 | RESETTING PLURIPOTENT STEM CELLS | CAMBRIDGE ENTPR LTD (GB) | 2025-07-09 | — | — | EP | claimed |
| US-20250197803-A1 | A METHOD OF DIFFERENTIATING AN INDUCED PLURIPOTENT STEM CELL INTO A RETINAL PIGMENT EPITHELIAL CELL, A RETINAL PIGMENT EPITHELIAL CELL AND METHODS OF USING THE RETINAL PIGMENT EPITHELIAL CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-06-19 | — | — | US | claimed |
| EP-4568707-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | EndoRel Biosciences LLC (US) | 2025-06-18 | — | — | EP | claimed |
| WO-2015191986-A1 | METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE | GENENTECH, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| WO-2015191996-A1 | METHODS OF TREATING AND PREVENTING CANCER DRUG RESISTANCE | GENENTECH, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| EP-2512476-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | Novartis AG (CH) | 2012-10-24 | — | — | EP | claimed |
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | claimed |
| EP-2497825-A1 | Novel method for rapid and efficient generation of neuroectoderm cells and peripheral neurons from pluripotent stem cells | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-09-12 | — | — | EP | claimed |
| WO-2011075620-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | NOVARTIS AG (CH) | 2011-06-23 | — | — | WO | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002124-A1 | ENHANCING NEURONAL DIFFERENTIATION OF VENTRAL MIDBRAIN NEURAL PROGENITOR CELLS | L1CAM, NES, NOTCH1 | FGFR1 46/4885FGFR2 36/4885FGFR4 332/4885 |
| US-20120258940-A1 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS | FGFR3, FGFR2, FGFR1 | FGFR1 3/4885FGFR2 2/4885FGFR4 5/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | FGFR1 87/4885FGFR2 220/4885FGFR4 70/4885 |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | SSB, METTL16, TLR9 | FGFR1 3341/4885FGFR2 3291/4885FGFR4 4450/4885 |
| US-20250230208-A1 | METHODS FOR TREATING EYE DISEASES USING LIPID BINDING PROTEIN-BASED COMPLEXES | CETP, HDLBP, APOB | FGFR1 4426/4885FGFR2 4625/4885FGFR4 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.